Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEADE-CRC-03 phase 3 study of precemtabart tocentecan with or without bevacizumab versus trifluridine/tipiracil plus bevacizumab in previously treated metastatic colorectal cancer
CTR20262356Phase 3Active
- Sponsor
- Merck KGaA
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of precemtabart tocentecan in colorectal cancer (CRC), sponsored by Merck KGaA. Started May 2026; status: active.
02
Drugs
precemtabart tocentecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20262356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262356.